PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 65.96

Change

0.00 (0.00)%

Market Cap

USD 6.62B

Volume

0.62M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.57 (+1.04%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

+14.31 (+1.48%)

USD 107.30B
MRNA Moderna Inc

+0.22 (+0.17%)

USD 44.96B
BNTX BioNTech SE

-2.37 (-2.55%)

USD 22.34B
ARGX argenx NV ADR

-10.79 (-2.87%)

USD 22.23B
ALNY Alnylam Pharmaceuticals Inc

-1.82 (-1.20%)

USD 19.13B
BGNE BeiGene Ltd

+1.82 (+1.06%)

USD 18.28B
GMAB Genmab AS

+0.33 (+1.11%)

USD 18.26B
RPRX Royalty Pharma Plc

-0.61 (-2.19%)

USD 16.78B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.77%)

USD 15.29B

ETFs Containing PCVX

HVAX:CA 4.86 % 0.00 %

N/A

N/A
SBIO ALPS Medical Breakthrough.. 4.60 % 0.50 %

-0.44 (0%)

USD 0.11B
VTWG Vanguard Russell 2000 Gro.. 0.53 % 0.20 %

-0.18 (0%)

USD 0.91B
GERM ETFMG Treatments Testing .. 0.00 % 0.00 %

-0.24 (0%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.03% 59% D- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.03% 59% D- 67% D+
Trailing 12 Months  
Capital Gain 28.33% 76% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.33% 76% C+ 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 27.55% 79% B- 84% B
Dividend Return 27.55% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.01% 53% F 32% F
Risk Adjusted Return 52.98% 94% A 82% B
Market Capitalization 6.62B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector